ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic.